Last reviewed · How we verify
NCT07068542: TROPION
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NA trial testing Sacituzumab Tirumotecan (SKB264) plus Tislelizumab in Advanced Thyroid Carcinoma in 94 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Zhejiang Provincial People's Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 94 |
| Start date | 1 July 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab — full drug profile →
- Sacituzumab Tirumotecan (SKB264) — full drug profile →
Conditions studied
- Advanced Thyroid Carcinoma — all drugs for Advanced Thyroid Carcinoma →
- Radioiodine-refractory Differentiated Thyroid Cancer — all drugs for Radioiodine-refractory Differentiated Thyroid Cancer →
- Poorly Differentiated Thyroid Carcinoma — all drugs for Poorly Differentiated Thyroid Carcinoma →
Sponsor
Zhejiang Provincial People's Hospital
Who can join
18 and older, any sex, with Advanced Thyroid Carcinoma or Radioiodine-refractory Differentiated Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, open-label, multi-cohort Phase II exploratory study designed to evaluate the efficacy and safety of sacituzumab tirumotecan with or without tislelizumab in patients with unresectable, locally advanced, or metastatic anaplastic thyroid carcinoma (ATC), poorly differentiated thyroid carcinoma (PDTC), or radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Patients with ATC will receive sacituzumab tirumotecan in combination with tislelizumab. Patients with PDTC and RAIR-DTC will receive sacituzumab tirumotecan monotherapy. The primary objective in the ATC cohort is overall survival (OS). In the PDTC and RAIR-DTC cohorts, the primary objective is progression-free survival (PFS) assessed by investigators per RECIST v1.1.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07068542
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Zhejiang Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07212634 — Cerebellar Transcranial Direct Current Stimulation for Dysphagia After Supratentorial Stroke · NA · not yet recruiting
- NCT07312422 — LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study · Phase 1, PHASE2 · recruiting
- NCT06975644 — Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) · NA · not yet recruiting
- NCT06979271 — Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07068542 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Provincial People's Hospital
- Last refreshed: 24 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07068542.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing